Volume 61, Issue 3 pp. 327-332
Coronary Artery Disease

Reduced vascular complications after percutaneous coronary interventions with a nonmechanical suture device: Results from the randomized RACE study

Timothy A. Sanborn MD

Corresponding Author

Timothy A. Sanborn MD

Evanston Northwestern Healthcare, Evanston, Illinois

Division of Cardiology, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Burch 300, Evanston, IL 60201Search for more papers by this author
J. David Ogilby MD

J. David Ogilby MD

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Search for more papers by this author
James M. Ritter MD

James M. Ritter MD

Christiana Care Health Services, Newark, Delaware

Search for more papers by this author
Gregg W. Stone MD

Gregg W. Stone MD

Lenox Hill Hospital, New York, New York

Search for more papers by this author
Bruce D. Klugherz MD

Bruce D. Klugherz MD

Abington Memorial Hospital, Abington, Pennsylvania

Search for more papers by this author
Ronald H. Fields MD

Ronald H. Fields MD

St. Mary Medical Center, Langhorne, Pennsylvania

Search for more papers by this author
Christopher C. White MD

Christopher C. White MD

Ochsner Clinic, New Orleans, Louisiana

Search for more papers by this author
Robert L. Wilensky MD

Robert L. Wilensky MD

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Search for more papers by this author
First published: 19 February 2004
Citations: 9

This article has been corrected since its original publication. Please click on the Erratum link above for further details.

Abstract

The objective of this study was to evaluate the safety and efficacy of a novel nonmechanical percutaneous suture device, X-Press, after diagnostic catheterization and percutaneous coronary interventions (PCIs) in the setting of glycoprotein IIb/IIIa inhibitor usage. Current percutaneous vascular suture devices remain mechanically complex and expensive and have not been shown to reduce major vascular complications. Using a 2:1 randomization scheme (2:1 ratio, device vs. compression), 393 patients undergoing diagnostic catheterization (n = 133) or PCI (n = 260) were randomized in the prospective Rapid Ambulation After Closure (RACE) study and evaluated for time to ambulation, time to hemostasis, treatment success, and incidence of major vascular complications. Glycoprotein IIb/IIIa inhibitors were used in 52% of PCI patients. There was a significant reduction in the primary efficacy endpoint of median time to ambulation for device compared to control with both diagnostic (2.2 vs. 6.2 hr; P = 0.0001) and PCI patients (4.1 vs. 14.7 hr; P = 0.0001). Device malfunction occurred in 3.1% patients without clinical sequalae. Equivalence in the primary safety endpoint, the incidence of major complications (vascular repair, ultrasound-guided compression, transfusion, or infection) at 14 days, was observed with the X-Press device (1/261; 0.4%) compared to control (3/132; 2.3%; P = 0.11). In PCI patients, half of whom received glycoprotein IIb/IIIa inhibitors, there was a significant reduction in the incidence of vascular complications in patients using the device (0/172; 0%) compared to control (3/88; 3.4%; P = 0.037). In diagnostic catheterization and PCI, a novel nonmechanical suture device reduced the time to ambulation and demonstrated equivalence in major complications compared to conventional compression techniques. The incidence of major complications after PCI was reduced with the device. Catheter Cardiovasc Interv 2004;61:327–332. © 2004 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.